[ad_1]
Balances blood sugar levels and helps with weight loss
Is this the breakthrough in the treatment of common diseases of diabetes and obesity? German scientists, who have successfully tested the new drug on humans for the first time, speak of excellent efficacy. The powerful new remedy not only reduces blood sugar levels, but also body weight, offering millions of people a new treatment alternative.
A team of researchers from the University of Leipzig is badociated with its partners to develop a new drug. tested in humans in a clinical trial. According to the results, the preparation shows excellent efficiency. The drug not only decreases the level of sugar in the blood, but also inhibits appetite and helps to lose weight. The results of the study were recently published in the journal "The Lancet".
Two old acquaintances: Diabetes and Obesity
Researchers say that genetic causes, obesity and obesity are the main causes of type 2 diabetes. "When patients have to inject insulin for a disease or receive insulin-increasing drugs, most of them continue to grow," says Professor Dr. Michael Stumvoll, director of study and professor of endocrinology at the University of Leipzig in a press release on the results of the study
Obesity causes diabetes and conversely
"We are sending patients into a vicious circle," reports the expert. If patients have diabetes because they are overweight, they will receive drugs that increase them even more. To break this vicious cycle, the team has developed a drug that reduces blood sugar levels without promoting obesity. The result is so good that the drug can also be used to treat obesity without diabetes.
A possible magic drug?
Scientists stress the peculiarity of the drug because it not only regulates blood sugar, it also works simultaneously filling. The subjects in the study showed an improvement in blood glucose while losing weight. According to the study, a type of double hormone is responsible for the revolutionary efficiency. The injected messenger protein stimulates so-called glucagon receptors, which control blood sugar. At the same time, receptors called GLP1 are stimulated, which has a beneficial effect on metabolism in several ways
Can also be used for obesity
Researchers report, among other things, that metabolic effects increase satiety in the brain. Thus, the drug also has great potential for use against obesity, regardless of the presence of diabetes. The drug is similar to the body's own hormone called oxyntomodulin. According to experts, this drug is clbadified as intestinal hormone filler, but has no effect on blood sugar.
Phase II was successfully completed
"Our study aimed to evaluate the efficacy, tolerability and safety of the new preparation. This type of study is called a Phase II study, in which an active substance is first tested on patients. The goal of this phase was to determine the best dose and monitor possible side effects.
Course of the study
The effectiveness was tested in 112 participants. A control group unknowingly received a placebo cure. During the test phase, subjects were hospitalized and closely monitored. In addition to monitoring various parameters such as blood glucose, heart rate, blood pressure and weight, stress tests were also performed, during which participants were served and the hormonal response observed
that the blood sugar with the new preparation does not increase as high as in the placebo group, "says the professor. Insulin reacts faster to combat the increase in blood sugar at mealtimes. Compared to the placebo group, all subjects were able to improve their blood glucose, including the lowest dose patients. Some side effects may include mild nausea and increased heart rate.
When will the medicine be available?
"Before the approval of the drug, it is important to balance the optimal effects with minimal side effects," says Stumvoll. However, he expects a market approval early in the next few years.
The success of the study also strengthens basic research
After successful study, the Leipzig researchers have around the professor. Michael Stumvoll merged with basic researchers in Munich and founded a new institute. The Leipzig-based Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG) is to transfer other drug candidates from basic research to clinical applications in similar studies in the US. years to come. (Vb)
[ad_2]
Source link
